Drugs / EMZ702
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00230854 | Aug 2005 → Jul 2007 | chronic hepatitis C virus infection | OPKO Health, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EMZ702 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00230854 ↗ |
| Route | Intravenous | “EMZ702 will be administered intravenously twice a week” NCT00230854 ↗ |